BiotechTube
Accentus Medical

Accentus Medical

Oxford, United Kingdom· Est. 2010

Accentus Medical is a leading medical technology company with over 20 years of expertise in developing and supplying advanced surface coating technologies for implantable devices. Its core technologies—Acusure® plasma spray coatings and Agluna®/Acusure Ag® silver antimicrobial treatments—are designed to improve bone/tissue integration and reduce post-operative infection risks. The company operates from the Harwell Campus innovation hub, collaborates globally with major device manufacturers, and has recently been acquired by the STS Group, marking a new chapter in its growth.

accentus-medical.com

Private Company

Total funding raised: $2.3M

AI Company Overview

Accentus Medical is a leading medical technology company with over 20 years of expertise in developing and supplying advanced surface coating technologies for implantable devices. Its core technologies—Acusure® plasma spray coatings and Agluna®/Acusure Ag® silver antimicrobial treatments—are designed to improve bone/tissue integration and reduce post-operative infection risks. The company operates from the Harwell Campus innovation hub, collaborates globally with major device manufacturers, and has recently been acquired by the STS Group, marking a new chapter in its growth.

OrthopaedicsSpinal SurgerySurgical Oncology

Technology Platform

A proprietary platform combining thermal plasma spray technology for implant fixation (Acusure®) with innovative silver ion integration methods (Agluna®, Acusure Ag®) to create antimicrobial, biocompatible surfaces for medical devices.

Funding History

2
Total raised:$2.3M
Grant$500KNov 15, 2021
Seed$1.8MSep 15, 2020

Opportunities

Significant growth opportunities exist in expanding the use of its proprietary silver antimicrobial technologies (Agluna®, Acusure Ag®) from niche oncology applications into the massive mainstream joint replacement market, driven by the urgent need to combat periprosthetic infections.
Geographic expansion, particularly in North America and Asia, and development of next-generation combination surface technologies present further avenues for growth.

Risk Factors

Key risks include dependence on a concentrated customer base of large device manufacturers, potential technological disruption from new coating methods, regulatory changes impacting device approvals, and execution risks associated with integrating into the new parent company, the STS Group.

Competitive Landscape

Accentus Medical competes with in-house coating divisions of large orthopaedic firms (e.g., Stryker, Zimmer Biomet) and specialized coating service providers. Its differentiation lies in its over 20-year clinical heritage, its unique Agluna® silver integration technology (not just a coating), and its ability to offer combined fixation-antimicrobial solutions alongside regulatory testing services.